FY2022 Q3 Financial and R&D Update slide image

FY2022 Q3 Financial and R&D Update

Best percentage change in SOD from baseline by BICR Best percentage change in SOD from baseline by BICR (n=39)* Dato-DXd 100- 80- 60- 40 20 0 -20 -40. -60 -80 -100- 100- 50 -50- TROPION-PanTumor01 Study SABCS 2022, HR positive and HER2 low or negative BC Cohort Efficacy Antitumor Responses by BICR (n=39) a Postbaseline tumor assessments were not available for 1 patient at data cutoff. One patient was not confirmed to have a target lesion per BICR and therefore had a best overall response of non-CR/non-PD. Ongoing -100- 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Time, weeks Data Cutoff: July 22, 2022 TROPION-PanTumor01 Daiichi-Sankyo HR positive and HER2 low or negative BC Cohort Cohort of patients with HR positive and HER2 low or negative unresectable or metastatic BC in Ph1 trial to: evaluate safety and efficacy of Dato-DXd ■Dato-DXd showed encouraging and durable efficacy in patients with HR positive and HER2 low or negative BC who previously received median of 5 lines of treatment for metastatic disease • • Confirmed ORR and DCR were 27% and 85%, respectively mPFS was 8.3 months 95% patients were pretreated with CDK4/6 inhibitors Dato-DXd demonstrated a manageable safety profile with no new safety signals. The most common TEAEs were stomatitis, nausea, and fatigue Durable efficacy and manageable safety shown in TROPION-Pan Tumor01 raises confidence in TROPION-Breast01 study BC: breast cancer, BICR: blinded independent central review, DCR: disease control rate, HR: hormone receptor, mPFS: median progression-free survival, ORR: objective response rate, SABCS: San Antonio Breast Cancer Symposium, 23 TEAEs: treatment emergent adverse events
View entire presentation